Sex-specific differences in treatment outcomes for patients with HIV and AIDS

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 8, Issue 1, 2008, Pages 51-63

  Stenehjem, Edward ^a   Shlay, Judith C ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b DENVER PUBLIC HEALTH   (United States)

Author keywords

Access to care; Adherence; Antiretroviral therapy; Health disparity; HIV; Men; Sex; Treatment outcome; Women

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; MARAVIROC; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOLISM; ANTIBODY PRODUCTION; ANTIVIRAL ACTIVITY; ATROPHY; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DEVELOPING COUNTRY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENCY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; GASTROINTESTINAL TOXICITY; HEALTH CARE ACCESS; HEART INFARCTION; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HYPERLACTATEMIA; HYPERTROPHY; IMMUNE RESPONSE; INTRAUTERINE INFECTION; INTRAVENOUS DRUG ABUSE; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER TOXICITY; LONG TERM EXPOSURE; MORTALITY; NEUROTOXICITY; PATIENT COMPLIANCE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEX DIFFERENCE; SEX ROLE; SURVIVAL RATE; SURVIVAL TIME; TERATOGENICITY; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 40749159576     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.8.1.51     Document Type: Review

References (86)

1. Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296(7), 827-843 (2006).
2. McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. AIDS 13(13), 1687-1695 (1999).
3. Farzadegan H, Hoover DR, Astemborski J et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet 352(9139), 1510-1514 (1998).
4. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N. Engl. J. Med. 344(10), 720-725 (2001).
5. Junghans C, Low N, Chan P, Witschi A, Vernazza P, Egger M. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS 13(18), 2547-2554 (1999).
6. Murri R, Lepri AC, Phillips AN et al. Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N.A. study. J. Acquir. Immune Defic. Syndr. 34(2), 184-190 (2003).
7. Napravnik S, Poole C, Thomas JC, Eton JJ Jr. Gender difference in HIV RNA levels: a meta-analysis of published studies. J. Acquir. Immune Defic. Syndr. 31(1), 11-19 (1002).
8. Katzenstein DA, Hammer SM, Hughes MD et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N. Engl. J. Med. 335(15), 1091-1098 (1996).
9. Andersen R, Bozzerte S, Shapiro M et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. Health Serv. Res. 35(2), 389-416 (2000).
10. Cunningham WE, Markson LE, Andersen RM et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the united states. HCSUS Consortium. HIV Cost and Services Utilization. J. Acquir. Immune Defic. Syndr. 25(2), 115-123 (2000).
11. McNaghten AD, Hanson DI, Dworkin MS, Jones JL. Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients. J. Acquir. Immune Defic. Syndr. 32(5), 499-505 (2003).
12. Mocroft A, Gill MJ, Davidson W, Phillips AN. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J. Acquir. Immune Defic. Syndr. 24(5), 475-482 (2000).
13. Fardet L, Mary-Krause M, Heard I, Partisani M, Costagliola D. Influence of gender and HIV transmission groups on initial highly active antiretroviral therapy prescription and treatment response. HIV Med. 7(8), 520-529 (2006).
14. Reif S, Whetten K, Thielman N. Association of race and gender with use of antiretroviral therapy among HIV-infected individuals in the southeastern United States. South. Med. J. 100(8), 775-781 (2007).
15. Gebo KA, Fleishman JA, Conviser R et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J. Acquir. Immune Defic. Syndr. 38(1), 96-103 (2005).
16. Giordano TP, White AC Jr, Sajja P et al. Factors associated with the use of highly active antiretrovital therapy in patients newly entering care in an urban clinic. J. Acquir. Immune Defic. Syndr. 32(4), 399-405 (2003).
17. Muula AS, Ngulube TJ, Siziya S et al. Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review. BMC Public Health 7, 63 (2007).
18. Perez F, Zvandaziva C, Engelsmann B, Dabis F. Acceptability of routine HIV testing ('opt-out') in antenatal services in two rural districts of Zimbabwe. J. Acquir. Immune Defic. Syndr. 41(4), 514-520 (2006).
19. Manzi M, Zachariah R, Teck R et al. High acceptability of voluntary counseling and HIV-testing but unacceptable loss to follow up in a prevention of mother-to-child HIV transmission programme in rural Malawi: scaling-up requires a different way of acting. Trop. Med. Int. Health 10(12), 1242-1250 (2005).
20. Rankin WW, Brennan S, Schell E, Laviwa J, Rankin SH. The stigma of being HIV-positive in Africa. PLoS Med. 2(8), E247 (2005).
21. Nicastri E, Angeletti C, Palmisano L et al. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS 19(6), 577-583 (2005).
22. Moore AL, Kirk O, Johnson AM et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J. Acquir. Immune Defic. Syndr. 32(4), 452-461 (2003).
23. Perez-Hoyos S, Rodriguez-Arenas MA, Garcia de la Hera M et al. Progression to AIDS and death and response to HAART in men and women from a multicenter hospital-based cohort. J. Women's Health 16(7), 1052-1061 (2007).
24. Moore AL, Sabin CA, Johnson MA, Phillips AN. Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. J. Acquir. Immune Defic. Syndr. 29(2), 197-202 (2002).
25. Kumar PN, Rodriguez-French A, Thompson MA et al. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med. 7(2), 85-98 (2006).
26. + lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J. Infect. Dis. 195(3), 425-431 (2007).
27. Egger M, May M, Chene G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360(9327), 119-129 (2002).
28. Porter K, Babiker A, Bhaskaran K et al. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 362(9392), 1267-1274 (2003).
29. O'Connell JM, Braitstein P, Hogg RS et al. Age, adherence and injection drug use predict virological suppression among men and women enrolled in a population-based antiretroviral drug treatment programme. Antivir. Ther. 8(6), 569-576 (2003).
30. Collazos J, Asensi V, Carton JA. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART. AIDS 21(7), 835-843 (2007).
31. Hunt PW, Decks SG, Rodriguez B et al Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 17(13), 1907-1915 (2003).
32. Kuyper LM, Wood E, Montaner JS, Yip B, O'Connell JM, Hogg RS. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-Infected patients in a population-based cohort. J. Acquir. Immune Defic. Syndr. 37(4), 1470-1476 (2004).
33. Abgrall S, Yeni PG, Bouchaud O, Costagliola D. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir. AIDS 20(16), 2099-2106 (2006).
34. Hoen B, Fournier I, Lacabaratz C et al. Structured treatment interruptions in primary HIV-1 infection: the ANRS 100 PRIMSTOP trial. J. Acquir. Immune Defic. Syndr. 40(3), 307-316 (2005).
35. Bedimo R, Chen RY, Westfall AO, Raper JL, Allison JJ, Saag MS. Sustained HIV viral suppression following treatment interruption: an observational study. AIDS Res. Hum. Retroviruses 22(1), 40-44 (2006).
36. + count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355(22), 2283-2296 (2006).
37. Kilaru KR, Kumar A, Sippy N, Carter AO, Roach TC. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country. HIV Med. 7(2), 99-104 (2006).
38. Ferradini L, Jeannin A, Pinoges L et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367(9519), 1335-1342 (2006).
39. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L. Genetic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 20(8), 1163-1169 (2006).
40. DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 20(10), 1391-1399 (2006).
41. Braga P, Cardoso MR, Segurado AC. Gender differences in survival in an HIV/AIDS cohort from Sao Paulo, Brazil. AIDS Patient Care STDS 21(5), 321-328 (2007).
42. Ammassari A, Trotta MP, Murri R et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J. Acquir. Immune Defic. Syndr. 31(Suppl. 3), S123-S127 (2002).
43. Turner BJ, Laine C, Cosler L, Hauck WW. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. J. Gen. Intern. Med. 18(4), 248-257 (2003).
44. Berg KM, Demas PA, Howard AA, Schoenbaum EE, Gourevitch MN, Arnsten JH. Gender differences in factors associated with adherence to antiretroviral therapy. J. Gen. Intern. Med. 19(11), 1111-1117 (2004).
45. Howard AA, Arnsten JH, Lo Y et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS 16(16), 2175-2182 (2002).
46. Sayles JN, Wong MD, Cunningham WE. The inability to take medications openly at home: does it help explain gender disparities in HAART use? J. Womens Health (Larchmt) 15(2), 173-181 (2006).
47. Shah B, Wilshe L, Saple DG et al. Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India. Clin. Infect. Dis. 44(9), 1235-1244 (2007).
48. Haug NA, Sorensen JL, Lollo ND, Gruber VA, Delucchi KL, Hall SM. Gender differences among HIV-positive methadone maintenance patients enrolled in a medication adherence trial. AIDS Care 17(8), 1022-1029 (2005).
49. Kim TW, Palepu A, Cheng DM, Libman H, Saitz R, Samet JH. Factors associated with discontinuation of antiretroviral therapy in HIV-infected patients with alcohol problems. AIDS Care 19(8), 1039-1047 (2007).
50. Wood E, Montaner JS, Yip B et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ 169(7), 656-661 (2003).
51. Moss AR, Hahn JA, Perry S et al. Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study. Clin. Infect. Dis. 39(8), 1190-1108 (2004).
52. Palepu A, Tyndall MW, Chan K, Wood E, Mbntaner JS, Hogg RS. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes. Antivir. Ther. 9(5), 713-719 (2004).
53. d'Arminio Monforte A, Cozzi-Lepri A, Phillips A et al. Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian cohort of antiretroviral-naive patients. J Acquir. Immune Defic. Syndr. 38(4), 407-416 (2005).
54. Touloumi G, Pantazis N, Antoniou A, Stirnadel HA, Walker SA, Porter K. Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences. J. Acquir. Immune Defic. Syndr. 42(5), 554-561 (2006).
55. Arnsten JH, Demas PA, Grant RW et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J. Gen. Intern. Med. 17(5), 377-381 (2002).
56. Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 17(15), 2159-2168 (2003).
57. Stretcher BN, Pesce AJ, Frame PT, Stein DS. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 38(7), 1541-1547 (1994).
58. Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin. Infect. Dis. 45(2), 254-260 (2007).
59. Geddes R, Knight S, Moosa MY, Reddi A, Uebel K, Sunpath H. A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S. Afr. Med. J. 96(8), 722-724 (2006).
60. Bersoff-Matcha SJ, Miller WC, Aberg JA et al. Sex differences in nevirapine rash. Clin. Infect. Dis. 32(1), 124-129 (2001).
61. Ofotokun I, Chuck SK. Hitti JE. Andretroviral pharmacokinetic profile: a review of sex diffirences. Gend. Med. 4(2), 106-119 (2007).
62. van Leth F, Andrews S, Grinsztejn B et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 19(5), 463-471 (2005).
63. Smith CJ, Sabin CA, Youle MS et al. Response to efavirenz-conmining regimens in previously antiretroviral-naive HIV-positive patients: the role of gender. J. Acquir. Immune Defic. Syndr. 46(1), 62-67 (2007).
64. Friis-Moller N, Sabin CA, Weber R et al. Combination antiretraviral therapy and the risk of myocardial infarction. N. Engl. J. Med. 349(21), 1993-2003 (2003).
65. Friis-Moller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med. 356(17), 1723-1735 (2007).
66. Richter A, Pladevall M, Manjunath R et al. Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV-infected patients: a retrospective cohort study. HIV Med. 6(2), 79-90 (2005).
67. Galli M, Cozzi-Lepri A, Ridolfo AL et al. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. Arch. Intern. Med. 162(22), 2621-2628 (2002).
68. Bonfanti P, Gulisano C, Ricci E et al. Risk factors for lipodystrophy in the CISAI cohort. Biomed. Pharmacother. 57(9), 422-427 (2003).
69. Heath KV, Chan KJ, Singer J, O'Shaughnessy MV, Montaner JS, Hogg RS. Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy. Int. J. Epidemiol. 31(5), 1016-1020 (2002).
70. Santos CP, Felipe YX, Braga PE, Ramos D, Lima RO, Segurado AC. Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors. AIDS 19(Suppl. 4), S14-S21 (2005).
71. Galli M, Veglia F, Angarano G et al. Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. J. Acquir. Immune Defic. Syndr. 34(1), 58-61 (2003).
72. Rakotoambinina B, Medioni J, Rabian C, Jubault V, Jais JP, Viard JP. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J. Acquir. Immune Defic. Syndr. 27(5), 443-449 (2001).
73. Boufassa F, Dulioust A, Lascaux AS et al. Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response. HIV Clin. Trials 2(4), 339-345 (2001).
74. Iwamoto M, Wenning LA, Petry AS et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Mol. Ther. 83(2), 293-299 (2008).
75. Markowitz M, Nguyen BY, Gonizzo E et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr. 46(2), 125-133 (2007).
76. Grinsztejn B, Nguyen BY, Katlama C et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatmen-expcrienced patients with multidrug-resistant virus: a Phase II randomised controlled trial. Lancet 369(9569), 1261-1269 (2007).
77. Saag M, Ive P, Heera. J, Tawadrous M, DeJesus E. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV 1: week 48 results of the MERIT study. Presented at: International AIDS Society. Sydney. Australia (2007).
78. Litezari J, Goodrich J, DeJesus E, Lampiris H. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a Phase 2b/ 3 Study in the US and Canada. Presented at: Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA (2007) (Abstract 104bLB).
79. Nelson M, Fatkenheuer G, Konourina I, Lazzarin A. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results. Presented at: Conference on Ratroviruses and Opportunistic Infections. Los Angeles, CA, USA (2007) (Abstract 104aLB).
80. de Mendoza C, Rodriguez C, Garcia F et al. Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. J. Antimicrob. Chemother. 59(4), 698-704 (2007).
81. Portales P, Clot J, Corbeau P. Sex differences in HIV-1 viral load due to sex difference in CCR5 expression. Ann. Int. Med. 134(1), 81-82 (2001).
82. Madruga JV, Cahn P, Grinsztejn B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370(9581), 29-38 (2007).
83. Lazzarin A, Campbell T, Clotet B et al. Efficacy and safety of TMC125.(etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370(9581), 39-48 (2007).
84. Gebo KA. HIV and aging: implications for patient management. Drugs Aging 23(11), 897-913 (2006).
85. Gebo KA, Moore RD. Treatment of HIV infection in the older patient. Expert Rev. Anti-infective Ther. 2(5), 733-743 (2004).
86. Paul SM, Martin RM, Lu SE, Lin Y. Changing trends in human immunodeficiency virus and acquired immunodeficiency syndrome in the population aged 50 and older. J. Am. Geriatr. Soc. 55(9), 1393-1397 (2007).